Leqselvi ™ (deuruxolitinib) is now available for the treatment of adults with severe alopecia areata.

Sun Pharma has introduced LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for severe alopecia areata after settling a patent dispute with Incyte. Approved by the FDA and backed by strong clinical ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

The International Medical Derm Summit 2025 highlighted China's dermatological advancements, fostering global collaboration ...

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found.

A new study published in the Journal of American Medical Association showed that individuals with autoimmune skin diseases ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...